HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis (Q43821840)

27 November 2017

title

HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis (English)

1 reference

27 November 2017

0 references

1 reference

1 reference

1 reference

1 reference

9

Dieter Häussinger

1 reference

27 November 2017

Andreas Erhardt

1

1 reference

27 November 2017

Andrea Maschner-Olberg

2

1 reference

27 November 2017

Claudia Mellenthin

3

1 reference

27 November 2017

Günther Kappert

4

1 reference

27 November 2017

Ortwin Adams

5

1 reference

27 November 2017

Andreas Donner

6

1 reference

27 November 2017

Reinhard Willers

7

1 reference

27 November 2017

Claus Niederau

8

1 reference

27 November 2017

language of work or name

1 reference

1 March 2003

1 reference

27 November 2017

published in

Journal of Hepatology

1 reference

27 November 2017

volume

38

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

335-342

1 reference

Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Measurements of iron status in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron and chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Prevalence of Hemochromatosis among 11,065 Presumably Healthy Blood Donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Global prevalence of putative haemochromatosis mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

A population-based study of the clinical expression of the hemochromatosis gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Haemochromatosis in the new millennium.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron, oxidative stress and liver fibrogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Long-term survival in patients with hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

The immunological system in hemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900415-4

7 January 2021

10.1016/S0168-8278(02)00415-4

Identifiers

DOI

1 reference

27 November 2017

1 reference